Dr. Reddy's Laboratories Ltd (RDY) Stock Price & How to Invest
Last updated July 2026
Short answer
RDY is the US-listed ADR of Dr. Reddy's Laboratories, a large Indian generic and specialty drugmaker whose US business just lost its lucrative generic-Revlimid exclusivity, so the near-term story is whether biosimilars, GLP-1 (semaglutide), and the acquired Nicotinell consumer-health line can refill that revenue hole.
RDY stock price
As of 2026-07-14, Dr. Reddy's Laboratories Ltd (RDY) last closed at $12.84, down 11.6% over the past year. Over the past 52 weeks it has traded between $12.46 and $15.38.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Dr. Reddy's Laboratories Ltd's investor relations page. Walnut is informational, not investment advice.
What does Dr. Reddy's Laboratories Ltd (RDY) do?
Dr. Reddy's Laboratories, founded in 1984 and based in Hyderabad, India, is one of the largest Indian pharmaceutical companies, spanning active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. Its therapeutic focus areas include gastrointestinal, cardiovascular, diabetes, oncology, pain management, and dermatology, and its major markets are the United States, India, Russia and CIS, Europe, and emerging markets. The US generics arm (Dr. Reddy's Laboratories, Inc., based in Princeton, New Jersey) is the single largest revenue contributor, and the company trades on the NYSE as an American Depositary Receipt (ADR) while also listing in India.
The FY2026 investment picture is defined by a transition. Dr. Reddy's limited-competition window on generic Revlimid (lenalidomide) ended on January 31, 2026, removing an outsized, high-margin US profit stream (previously estimated near $250 million of quarterly revenue), which crushed Q4 FY26 margins and profit. Management is pivoting toward biosimilars (denosumab, rituximab), generic GLP-1 weight-loss and diabetes therapy (semaglutide, launched in Canada and India), and the acquired ex-US Nicotinell nicotine-replacement consumer-health business bought from Haleon. The core company remains solidly profitable and cash-generative, so the debate is about the pace and quality of growth that replaces the Revlimid windfall.
What's driving Dr. Reddy's Laboratories Ltd (RDY)?
1. Biosimilars ramp
Dr. Reddy's is building a biosimilar franchise to offset the small-molecule generic squeeze, with denosumab launched in the EU, rituximab approved in Canada in February 2026, and US biosimilar entries targeted for 2026-2027. Biosimilars carry higher barriers to entry and longer competitive runways than plain generics, which could support more durable margins if launches land on schedule.
2. GLP-1 / semaglutide opportunity
The company was first to market generic semaglutide injection in Canada (launched May 2026) and launched it in India under the brand Obeda on day one of loss of exclusivity, plus received authorization for semaglutide tablets in India. GLP-1 weight-loss and diabetes demand is very large, and early-mover generic positioning in markets where exclusivity has lapsed is a potential multi-year growth lever.
3. Consumer health and Nicotinell
Dr. Reddy's acquired Haleon's ex-US nicotine-replacement-therapy business (Nicotinell and related brands) for roughly 500 million pounds (about $633 million), adding a branded consumer-health revenue stream generating around 217 million pounds in annual sales. This diversifies the mix away from volatile US generics toward steadier branded OTC cash flows.
4. Diversified geographic base
Beyond the US, the company earns meaningful revenue in India, Russia and CIS, Europe, and other emerging markets, which cushions US pricing pressure. A broad API and formulations manufacturing footprint gives it vertical integration and cost control across its portfolio.
What are the risks to Dr. Reddy's Laboratories Ltd (RDY)?
The loss of generic Revlimid exclusivity in early 2026 removed a large, high-margin profit stream, and Q4 FY26 showed the impact: revenue fell about 11.6% year over year and gross margin dropped to roughly 44.8% from about 55.6% a year earlier. US generic drug pricing is chronically deflationary and highly competitive, so new launches must run fast just to stand still. Biosimilar and GLP-1 ambitions face regulatory, manufacturing, and competitive execution risk, and any US FDA inspection or compliance issue at a plant could disrupt supply. As an ADR, US investors also carry currency (rupee/dollar) and India-specific regulatory and disclosure exposure. Shelf-stock-adjustment and price-reduction charges (a roughly $50 million revenue reduction on lenalidomide in Q4 FY26) show how quickly pricing dynamics can hit reported results.
How is Dr. Reddy's Laboratories Ltd (RDY) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Dr. Reddy's Laboratories Ltd's investor relations page or your broker.
- Revenue (FY26): ~$4.0B
- Market cap: ~$12.8B
- P/E (normalized): ~27x
- FY26 EBITDA margin: ~22.8%
- Forward dividend yield: ~0.6%
- FY26 revenue growth: ~3.2%
FY2026 (year ended March 31, 2026) revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, but Q4 profit before tax collapsed to about 2.6% of revenue as the Revlimid exclusivity ended and margins compressed. The stock trades around a mid-20s price-to-earnings multiple with a low payout ratio (near 15%) and a modest sub-1% dividend yield. Figures are approximate, converted from Indian rupee reporting, and can shift with exchange rates and each quarterly release.
Who competes with Dr. Reddy's Laboratories Ltd (RDY)?
Indian generic and specialty pharma peers
Sun Pharmaceutical, Cipla, Lupin, Aurobindo Pharma, and Zydus compete directly in US generics, Indian branded generics, and biosimilars, and several are pursuing the same GLP-1 and complex-generic opportunities.
Global generic and biosimilar makers
Teva, Viatris, Sandoz, and Amneal compete on US generic launches and biosimilar portfolios, where scale, manufacturing quality, and speed to market drive share and pricing.
Consumer health / nicotine-replacement rivals
In the acquired Nicotinell franchise, Dr. Reddy's competes with players such as Kenvue (Nicorette), Perrigo, and other OTC and NRT suppliers on brand strength and retail distribution.
How to invest in Dr. Reddy's Laboratories Ltd (RDY)
There are three common ways to get RDY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so RDY sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where RDY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Dr. Reddy's Laboratories Ltd (RDY)
RDY is a profitable, cash-generative global generics maker navigating a well-flagged Revlimid earnings cliff, and its trajectory hinges on how fast its biosimilar, GLP-1, and consumer-health pivots scale.
More on Dr. Reddy's Laboratories Ltd (RDY)
Whether RDY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RDY a buy?, and where the stock could go from here in the RDY stock forecast.
For income investors, whether RDY pays a dividend and how the payout looks is covered in does RDY pay a dividend?
Build a basket around RDY with Walnut
Use Dr. Reddy's Laboratories Ltd as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is RDY?
+
RDY is the NYSE-listed American Depositary Receipt (ADR) of Dr. Reddy's Laboratories, a large Indian pharmaceutical company that makes generics, branded generics, biosimilars, APIs, and over-the-counter products. It also lists on Indian exchanges.
Is RDY a US company?
+
No. Dr. Reddy's is headquartered in Hyderabad, India, and RDY is an ADR that lets US investors hold the shares in dollars on the NYSE. That means currency and India-specific regulatory factors apply.
What is the Revlimid cliff and why does it matter?
+
Dr. Reddy's limited-competition period for generic Revlimid (lenalidomide) ended January 31, 2026, opening the market to unlimited competitors. That removed a large, high-margin US profit stream (previously near $250 million of quarterly revenue), which sharply pressured FY26 Q4 profit and margins.
How is Dr. Reddy's trying to replace that revenue?
+
It is scaling biosimilars (denosumab, rituximab), generic GLP-1 therapies like semaglutide (launched in Canada and India), and the acquired ex-US Nicotinell nicotine-replacement consumer-health business. The open question is how quickly these ramp relative to the Revlimid decline.
Does RDY pay a dividend?
+
Yes, but a modest one. The forward dividend yield is roughly 0.6% with a low payout ratio near 15%, reflecting a company that reinvests most of its cash into R&D and its product pipeline.
What were Dr. Reddy's FY2026 results?
+
FY26 revenue was about 335,933 million rupees (roughly $4.0 billion), up about 3.2%, with EBITDA margin near 22.8%. However, Q4 FY26 revenue fell about 11.6% year over year and margins compressed sharply as the Revlimid exclusivity ended.
Who are Dr. Reddy's main competitors?
+
Indian peers like Sun Pharma, Cipla, Lupin, and Aurobindo; global generic and biosimilar makers like Teva, Viatris, and Sandoz; and in consumer health, nicotine-replacement rivals such as Kenvue (Nicorette) and Perrigo.
What are the biggest risks for RDY?
+
The post-Revlimid earnings reset, chronic US generic price deflation, execution risk on biosimilar and GLP-1 launches, FDA plant-compliance risk, and ADR-specific currency and India regulatory exposure. Walnut is not an investment adviser, so treat this as descriptive context rather than a recommendation.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Dr. Reddy's Laboratories Ltd's investor relations page or your broker before making investment decisions.